Relay Therapeutics officer plans $1.0M share sale
Relay Therapeutics, Inc. (RLAY) reports that officer Peter Rahmer has filed a Rule 144 notice to sell up to 50,000 shares of common stock through Morgan Stanley Smith Barney LLC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. (RLAY) reports that officer Peter Rahmer has filed a Rule 144 notice to sell up to 50,000 shares of common stock through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $1,028,500, with an approximate sale date of 08/26/2026 on NASDAQ. The shares relate to Restricted Stock Units granted on 01/28/2025 by the issuer. Relay Therapeutics states that 219,141,631 shares of common stock are outstanding. The filing also notes prior 10b5-1 plan sales of 50,000 shares for $954,560 on 06/30/2026.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Units financial
10b5-1 regulatory
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for RLAY disclose about planned insider sales?
Were there recent 10b5-1 plan sales disclosed for RLAY?
AI-generated analysis. How Rhea-AI works. Not financial advice.